Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients

British Journal of Ophthalmology

Volumn 91, Issue 3, 2007, Pages 335-339

  Bodaghi, Bahram ^a,b   Gendron, Gael ^b   Wechsler, Bertrand ^b   Terrada, Céline ^b   Cassoux, Nathalie ^b   Huong, Du Le Thi ^b   Lemaitre, Claire ^b   Fradeau, Christine ^b   LeHoang, Phuc ^b   Piette, Jean Charles ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; STEROID; GLUCOCORTICOID;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BEHCET DISEASE; BLOOD CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE EXAMINATION; EYE FUNDUS; FEMALE; FEVER; FLU LIKE SYNDROME; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; NEUTROPENIA; OPTIC NEURITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RELAPSE; RETINA MACULA EDEMA; RETINA VASCULITIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THYROIDITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION; DRUG RESISTANCE; DRUG SCREENING; MIDDLE AGED; RECURRENT DISEASE;

ADOLESCENT; ADULT; BEHCET SYNDROME; CHILD; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS;

EID: 33947572363     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.101550     Document Type: Article

References (42)

1. Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina 2005;25:1-18.
2. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12.
3. Feron EJ, Rothova A, van Hagen PM, et al. Interferon-alpha 2b for refractory ocular Behcet's disease. Lancet 1994;343:1428.
4. Kotter I, Eckstein AK, Stubiger N, et al. Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 1998;82:488-94.
5. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, et al. Interferon alpha for ocular Behcet's disease. Acta Ophthalmol Scand 1997;75:720-2.
6. Dinning W. An overview of ocular manifestations. In: Recent advances in Behçet's disease. In: Lehner T, Barnes C, eds. London: Royal Society of Medicine, 1986:227-33.
7. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004;138:373-80.
8. Wechsler B, Du-Boutin LT. Interferons and Behcet's disease. Rev Med Interne 2002;23(Suppl 4):495-9s.
9. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 2000;8:293-301.
10. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31.
11. Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon alpha in Behcet disease: Review of the literature. Semin Arthritis Rheum 2004;33:320-35.
12. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;4:4.
13. Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 2001;80:263-70.
14. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335:1078-80.
15. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 1987;103:234-5.
16. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001;131:647-52.
17. Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92:467-71.
18. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
19. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002;138:467-71.
20. Krause L, Turnbull JR, Torun N, et al. Interferon alfa-2a in the treatment of ocular Adamantiades-Behcet's disease. Adv Exp Med Biol 2003;528:511-19.
21. O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behcet's disease. J Rheumatol 1998;25:1938-44.
22. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998;134:1010-16.
23. Kotter I, Deuter C, Stubiger N, et al. Interferon-α (IFN-α) application versus tumor necrosis factor-α antagonism for ocular Behcet's disease: focusing more on IFN. J Rheumatol 2005;32:1633.
24. Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J 2002;4:928-30.
25. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
26. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol 2004;22:S14-16.
27. Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behcet's disease. Adv Exp Med Biol 2003;528:557-9.
28. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004;138:648-50.
29. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-53.
30. Treusch M, Stubiger N, Vonthein R, et al. Influence of interferon-alpha on lymphocyte subpopulations in Behcet's disease. Adv Exp Med Biol 2003;528:533-5.
31. Treusch M, Vonthein R, Baur M, et al. Influence of human recombinant interferon-alpha2a (rhlFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford) 2004;43:1275-82.
32. Brasnu E, Wechsler B, Bran A, et al. Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associatea uveitis. Am J Ophthalmol 2005;140:746-8.
33. Lesire V, Arsene S, Piquemal R, et al. Familial recurrent bilateral panuveitis: efficiency of alpha interferon. Rev Med Interne 2003;24:464-8.
34. Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66.
35. Quesada JR, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986;4:234-43.
36. Alabdulaaly A, Rifkind J, Solow H, et al. Rescue of interferon induced bone marrow aplasia in a patient with chronic myeloid leukemia by allogeneic bone marrow transplant. Leuk Lymphoma 2004;45:175-7.
37. Hoffmann A, Kirn E, Krueger GR, et al. Bone marrow hypoplasia and fibrosis following interferon treatment. In Vivo 1994;8:605-12.
38. Perlemuter G, Bodaghi B, Le Hoang P, et al. Visual loss during interferon-alpha therapy in hepatitis C virus infection. J Hepatol 2002;37:701-2.
39. Schulman JA, Liang C, Kooragayala LM, et al. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003;110:437-42.
40. Lohmann CP, Kroher G, Bogenrieder T, et al. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. Lancet 1999;353:1326.
41. Norcia F, Di Maria A, Prandini F, et al. Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 1999;213:339-40.
42. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995;113:1041-4.